Meeting
2021 Genitourinary Cancers Symposium
Treatment response in the intact primary renal mass (P-Rmass) and its relationship to the overall response to treatment in patients with metastatic renal cell carcinoma (mRCC).
Authors
Hamid Emamekhoo
University of Wisconsin Carbone Cancer Center, Madison, WI
Hamid Emamekhoo , Hameem I Kawsar , Jens C. Eickhoff , Danubia Hester , Tristan Bice , Luna Acharya , Ellen Jaeger , Pedro C. Barata , Yousef Zakharia , Deepak Kilari , Elizabeth Marie Wulff-Burchfield , Christos Kyriakopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 329)
DOI
10.1200/JCO.2021.39.6_suppl.329
Abstract #
329
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparative effectiveness of first-line (1L) ipilimumab plus nivolumab (Ipi + Nivo) versus immune checkpoint inhibitors + tyrosine kinase inhibitors (ICI + TKI) in patients (pts) with intermediate or poor (I/P) risk metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Micah Ostrowski
Poster
2024 ASCO Genitourinary Cancers Symposium
Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.
First Author: Hyejee Ohm
Poster
2023 ASCO Quality Care Symposium
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database.
First Author: Joseph Vento
Poster
2023 ASCO Annual Meeting
Global circulating free DNA methylation and fragmentome deconvolution in patients with metastatic renal cell carcinoma treated with immunotherapy (GOLDEN).
First Author: Pavlina Spiliopoulou